Diabetes

Ranolazine added to glimepiride cuts HbA1c in T2DM

(HealthDay)—For patients with type 2 diabetes on background glimepiride therapy, but not metformin, addition of ranolazine is associated with a significant reduction in hemoglobin A1c (HbA1c), according to research published ...

Diabetes

Trends in insulin use, glycemic control explored

(HealthDay)—Since 1988, the proportion of patients with diabetes currently on any insulin has remained stable, according to research published online Dec. 30 in Diabetes Care.

Diabetes

Group medicine appointments effective for glycemic control

(HealthDay)—Medical management delivered via group medical appointments (GMAs) appears to be effective for glycemic control in patients with type 2 diabetes, according to research published in the November issue of Diabetes ...

Diabetes

GLP-1 receptor agonists can manage postprandial glucose

(HealthDay)—Glucagon-like peptide 1 (GLP-1) receptor agonists appear beneficial for postprandial glucose management in type 2 diabetes, according to a report published in the October issue of Clinical Diabetes.

Cardiology

Modest predictive power for HbA1c in atherosclerotic CVD risk

(HealthDay)—In the context of conventional cardiovascular disease (CVD) risk factors, hemoglobin A1c (HbA1c) has a modest effect on predicted atherosclerotic CVD risk, according to a study published online Sept. 8 in Circulation: ...

page 8 from 16